Biogen Appoints Sean Godbout as Vice President and Chief Accounting Officer

Biogen Inc., a leading biotechnology company, announced on January 13, 2025, the appointment of Sean Godbout as Vice President and Chief Accounting Officer. Effective March 1, 2025, Sean Godbout will assume the role of Global Corporate Controller, and will be designated as the principal accounting officer of the company.

This appointment follows the decision to transition Robin Kramer, the current Chief Accounting Officer, to the role of Chief Financial Officer, effective upon the retirement of Michael McDonnell, the current CFO, who is set to retire on March 1, 2025.

Sean Godbout, aged 50, has been with Biogen since 2007 and has been serving as the Global Corporate Controller since October 2023. He brings a wealth of experience to the role, having held various positions within the company, including Corporate Controller. Prior to joining Biogen, Mr. Godbout worked at PricewaterhouseCoopers LLP. He holds a B.S. from Cornell University in Industrial and Labor Relations, as well as an M.S. in Accounting and an MBA from Northeastern University. Mr. Godbout is a Certified Public Accountant in the state of Massachusetts.

In his new role, Sean Godbout will receive a base salary of $400,000 and will have the opportunity to participate in the company’s annual bonus plan, with a target bonus of 40% of his annual base salary. Additionally, his long-term incentive grant value for 2025 will be awarded in accordance with the company’s approved plans and guidelines.

As part of the executive severance plan for Vice Presidents, Mr. Godbout will be entitled to certain benefits in the event of a termination of employment, including severance payments and continuation of medical and dental insurance benefits under specific circumstances.

There are no undisclosed arrangements or relationships influencing Mr. Godbout’s appointment as Chief Accounting Officer and principal accounting officer. Furthermore, there are no familial ties between Mr. Godbout and any members of the company’s Board of Directors or executive officers.

This report was issued in compliance with the Securities Exchange Act of 1934. Wendell Taylor, Secretary of Biogen Inc., signed off on behalf of the company on January 15, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Biogen’s 8K filing here.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.